Product

Company

Clareo Health | PROV-MESH: Prophylactic Ovarian Cancer MESH

NCT07676370·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Hospital Vall d'Hebron

With

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

Female patients diagnosed with ovarian carcinoma.
Undergoing primary cytoreductive surgery, interval cytoreductive surgery, or delayed cytoreductive surgery after six cycles of chemotherapy.
Surgical procedure performed through a midline laparotomy.
Ability and willingness to provide written informed consent.

Surgery for recurrent ovarian cancer (secondary, tertiary, or subsequent cytoreductions).
Minimally invasive surgical approach.
Planned secondary cytoreductive surgery during the 24-month follow-up period.
Inability or unwillingness to comply with follow-up requirements.

The record

StatusRecruiting

PhaseNo phase

Taking part152

StartedJan 2026

UpdatedJun 30, 2026

Conditions

Where1